Optimization of multistage testing times and critical values in clinical trials

E. H. Brittain; K. R. Bailey

doi:10.2307/2532197

Optimization of multistage testing times and critical values in clinical trials

E. H. Brittain, K. R. Bailey

Health Sciences Research

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Optimal critical values and times of intermediate testing points are determined to minimize expected sample size in a variety of situations. Two- stage and three-stage models are considered for a variety of values of power. We investigate the robustness of the optimality parameters.

Original language	English (US)
Pages (from-to)	763-772
Number of pages	10
Journal	Biometrics
Volume	49
Issue number	3
DOIs	https://doi.org/10.2307/2532197
State	Published - Jan 1 1993

ASJC Scopus subject areas

Statistics and Probability
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
Agricultural and Biological Sciences(all)
Applied Mathematics

Access to Document

10.2307/2532197

Fingerprint Dive into the research topics of 'Optimization of multistage testing times and critical values in clinical trials'. Together they form a unique fingerprint.

Cite this

@article{9a62dca940e54c40bb3ff0c67e0fe0d4,

title = "Optimization of multistage testing times and critical values in clinical trials",

abstract = "Optimal critical values and times of intermediate testing points are determined to minimize expected sample size in a variety of situations. Two- stage and three-stage models are considered for a variety of values of power. We investigate the robustness of the optimality parameters.",

author = "Brittain, {E. H.} and Bailey, {K. R.}",

year = "1993",

month = jan,

day = "1",

doi = "10.2307/2532197",

language = "English (US)",

volume = "49",

pages = "763--772",

journal = "Biometrics",

issn = "0006-341X",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Optimization of multistage testing times and critical values in clinical trials

AU - Brittain, E. H.

AU - Bailey, K. R.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Optimal critical values and times of intermediate testing points are determined to minimize expected sample size in a variety of situations. Two- stage and three-stage models are considered for a variety of values of power. We investigate the robustness of the optimality parameters.

AB - Optimal critical values and times of intermediate testing points are determined to minimize expected sample size in a variety of situations. Two- stage and three-stage models are considered for a variety of values of power. We investigate the robustness of the optimality parameters.

UR - http://www.scopus.com/inward/record.url?scp=0027507502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027507502&partnerID=8YFLogxK

U2 - 10.2307/2532197

DO - 10.2307/2532197

M3 - Article

C2 - 8241372

AN - SCOPUS:0027507502

VL - 49

SP - 763

EP - 772

JO - Biometrics

JF - Biometrics

SN - 0006-341X

IS - 3

ER -